Knowledge * Excellence * Guidelines

Guidelines are key to modern rheumatological healthcare.

NICE accreditation 

NICE has accredited the process used by British Society for Rheumatology to produce its clinical guidance. Accreditation is valid for five years from February 2013. 


For full details on our accreditation visit nice.org.uk/accreditation

View the current Protocol we follow when developing our guidelines.

We neither seek nor accept industry funding for any of our guidelines. They are supported through our general finances.  

Creating our guidelines is a major voluntary endeavour by members, patients and practitioners from primary care and other specialities. We are grateful to everyone for their strenuous efforts in producing them.

Current guidelines:

Lupus

Guideline for the management of adults with Systemic Lupus Erythematosus

Executive summary >

Full guideline >

Audit tool >

2017 NICE Accredited

Due for revision in 2020

Sjögren’s Syndrome

Guideline for the management of adults with Primary Sjögren’s Syndrome

Executive summary >

Full guideline >

Audit tool >

2017 NICE Accredited

Due for revision in 2020

Gout

Guideline for the management of gout

Executive summary >

Full guideline >

Audit tool >

2017 NICE Accredited

Due for revision in 2020

DMARDs

Guideline for the prescription and monitoring of non-biologic Disease-Modifying Anti-Rheumatic Drugs

Executive summary >

Full guideline >

Audit tool >

2017 NICE Accredited

Due for revision in 2020

Axial spondyloarthritis

Guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics

Executive summary >

Full guideline >

Audit tool >

2016 NICE Accredited

Due for revision in 2019

Systemic sclerosis

Guideline for the treatment of systemic sclerosis

Executive summary >

Full guideline >

Audit content on page 10 of Full guideline

2016 NICE Accredited

Due for revision in 2019

Pregnancy and breastfeeding - part 1

Guideline on prescribing drugs in pregnancy and breastfeeding Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids

Executive summary >

Full guideline >

Audit tool >

2016 NICE Accredited

Due for revision in 2019

Pregnancy and breastfeeding - part 2

Guideline on prescribing drugs in pregnancy and breastfeeding Part 2: analgesics and drugs used in rheumatology practice

Executive summary >

Full guideline >

Audit tool >

2016 NICE Accredited

Due for revision in 2019

Intravenous tocilizumab

Guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis

Executive summary >

Full guideline >

2013 NICE Accredited

The Intravenous tocilizumab guideline is to become part of the new Biological DMARD safety guidelines in inflammatory arthritis due out in 2018

Psoriatic arthritis

Guideline for the treatment of psoriatic arthritis with biologics

See revision statement below

Executive summary >

Full guideline >

PsA guidelines revision statement >

2013 NICE Accredited

Due for revision in 2017

Hot swollen joint

Guideline for management of hot swollen joint in adults

The guideline for the management of the hot swollen joint was first published in 2006. Although there is not enough data to constitute a change in the guideline, there is sufficient new information to warrant an update within the next two years. Read the accompanying statement for more detail. March 2017.

Executive summary >

Full guideline >

Hot Joint guideline update >

Renewed and accepted unchanged in 2012. Reviewed again in 2017. An update of the guideline will be due within the next two years.

Due for revision in 2019

Polymyalgia rheumatica

Guideline for the management of polymyalgia rheumatica

SAGWG decided that the 2009 guideliine, originally due for review 20 2015, remains current. It is substantially the same as the new 2015 EULAR ACR guideline: Recommendations for the Management of Polymyalgia Rheumatica.

Executive summary >

Full guideline >

Due for revision in 2018

 

Guidelines under revision:

Anti-TNF therapies in RA

Guidelines on the safety of anti-TNF therapies in RA

Executive summary >

Due for publication early to mid 2018 when it becomes part of 'Biological DMARD safety guidelines in inflammatory arthritis.

Rituximab in RA

The use of Rituximab in rheumatoid arthitis

Executive summary >

Will become part of Biological DMARD safety guidelines in inflammatory arthritis

Giant cell arteritis

Management of giant cell arteritis

Executive summary >

Due for publication in 2018

 

New guidelines in development:

Adults patients with idiopathic inflammatory myopathy

Management of adult patients with idiopathic inflammatory myopathy (myositis)

Paediatric patients with idiopathic inflammatory myopathy

Management of paediatric patients with idiopathic inflammatory myopathy (myositis)